VISEN Pharmaceuticals
Company Profile
Business description
VISEN Pharmaceuticals is a late-stage, near-commercialization biopharmaceutical company focused on providing treatments in selected endocrinology diseases in China. It has one Core Product and two other pipeline drug candidates. Its Core Product, lonapegsomatropin, is a once-weekly long-acting growth hormone replacement therapy for the treatment of pediatric growth hormone deficiency (PGHD), a common short stature in patients aged under 18 caused by insufficient growth hormone. TransCon CNP (navepegritide), one of its key drug candidates, is a long-acting prodrug of c-type natriuretic peptide for the treatment of achondroplasia (ACH), a short-limbed dwarfism that results in severe skeletal complications and comorbidities.
Contact
69 Jiuzhang Road
Suite 3-108, Floor 3, Building B
Hengtai Lixiang Chuangxin Tower
Suzhou
CHNSector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
52
Stocks News & Analysis
stocks
What does big US court decision mean for Google’s parent company Alphabet?
stocks
Is this still an ASX share to own forever?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,140.50 | 11.00 | 0.12% |
CAC 40 | 7,656.10 | 42.82 | -0.56% |
DAX 40 | 23,625.66 | 144.67 | -0.61% |
Dow JONES (US) | 45,316.53 | 304.76 | -0.67% |
FTSE 100 | 9,204.98 | 11.89 | -0.13% |
HKSE | 25,417.98 | 359.47 | 1.43% |
NASDAQ | 21,621.71 | 85.98 | -0.40% |
Nikkei 225 | 43,018.75 | 438.48 | 1.03% |
NZX 50 Index | 13,223.53 | 90.33 | 0.69% |
S&P 500 | 6,464.58 | 37.50 | -0.58% |
S&P/ASX 200 | 8,871.20 | 8.60 | 0.10% |
SSE Composite Index | 3,812.51 | 46.64 | 1.24% |